Haemonetics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.7%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$1.4Bnext fiscal year
FY EPS (est.)
$5.30next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth (ex-CSL) Quarterly950.0%Target: Sustained high-single-digit growth
Adjusted Operating Margin Quarterly2,540.0%Target: Expansion driven by operational leverage
Free Cash Flow Annually209.9MTarget: Strong conversion of adjusted net income
Watch Items
- CSL Plasma U.S. supply agreement wind-down impactTrigger: Complete transition of nonrecurring revenueAction: Monitor organic growth rates excluding CSL to assess underlying business health.
- Integration of Vivasure Medical acquisitionTrigger: Commercialization milestones of PerQseal EliteAction: Track R&D progress and initial market adoption in vascular closure.
Research as of 19 Jun 2026